Increased active metabolite formation explains the greater platelet inhibition with prasugrel compared to high-dose clopidogrel

Journal of Cardiovascular Pharmacology

Volumn 50, Issue 5, 2007, Pages 555-562

  Payne, Christopher D ^a   Li, Ying Grace ^a   Small, David S ^a   Ernest II, C Steven ^a   Farid, Nagy A ^a   Jakubowski, Joseph A ^a   Brandt, John T ^a   Salazar, Daniel E ^b   Winters, Kenneth J ^a  

^a ELI LILLY AND COMPANY   (United States)

^b DAIICHI SANKYO INC   (United States)

Author keywords

Clopidogrel; P2Y12; Platelet inhibitor; Prasugrel; Thienopyridine

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; PRASUGREL;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLEEDING; BRUISING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; FEMALE; HUMAN; LOADING DRUG DOSE; MAINTENANCE DRUG DOSE; MALE; METABOLITE; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE AGGREGATION INHIBITION;

ADENOSINE DIPHOSPHATE; ADULT; AREA UNDER CURVE; BLOOD PLATELETS; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MIDDLE AGED; PIPERAZINES; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; THIOPHENES; TICLOPIDINE;

EID: 36348977461     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/FJC.0b013e3181492209     Document Type: Article

References (45)

1. Ruggeri ZM. Platelets in atherothrombosis. Nat Med. 2002;8:1227-1234.
2. Fuster V, Moreno PR, Fayad ZA, et al. Atherothrombosis and high risk plaque. I. Evolving concepts. J Am Coll Cardiol. 2005;46:937-954.
3. Bhatt DL, Steg PG, Ohman EM, et al. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA. 2006;295:180-189.
4. The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345:494-502.
5. Chen ZM, Jiang LX, Chen YP, et al. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet. 2005;366:1607-1621.
6. Steinhubl SR, Berger PB, Mann JT 3rd, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA. 2002;288:2411-2420.
7. Sabatine MS, Cannon CP, Gibson CM, et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med. 2005;352:1179-1189.
8. Bhatt DL, Topol EJ. Clopidogrel added to aspirin versus aspirin alone in secondary prevention and high-risk primary prevention: rationale and design of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. Am Heart J. 2004;148:263-268.
9. The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med. 1993;329:673-682.
10. Mehta SR, Yusuf S, Peters RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet. 2001;358:527-533.
11. Savi P, Pereillo JM, Uzabiaga MF, et al. Identification and biological activity of the active metabolite of clopidogrel. Thromb Haemost. 2000;84:891-896.
12. Clarke TA, Waskell LA. The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin. Drug Metab Dispos. 2003;31:53-59.
13. Kurihara A, Hagihara K, Kazui M, et al. In vitro metabolism of antiplatelet agent clopidogrel: cytochrome P450 isoforms responsible for two oxidative steps involved in the active metabolite formation [Abstract]. Drug Metab Rev. 2005;37(Suppl 2):99.
14. Hochholzer W, Trenk D, Frundi D, et al. Time dependence of platelet inhibition after a 600-mg loading dose of clopidogrel in a large, unselected cohort of candidates for percutaneous coronary intervention. Circulation. 2005;111:2560-64.
15. Gurbel PA, Samara WM, Bliden KP. Failure of clopidogrel to reduce platelet reactivity and activation following standard dosing in elective stenting: implications for thrombotic events and restenosis. Platelets. 2004;15:95-99.
16. Matetzky S, Shenkman B, Guetta V, et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation. 2004;109:3171-3175.
17. Gurbel PA, Bliden KP, Hiatt BL, et al. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation. 2003;107:2908-2913.
18. Bates ER, Lau WC, Bleske BE. Loading, pretreatment, and interindividual variability issues with clopidogrel dosing. Circulation. 2005;111:2557-2559.
19. Kastrati A, von Beckerath N, Joost A, et al. Loading with 600 mg clopidogrel in patients with coronary artery disease with and without chronic clopidogrel therapy. Circulation. 2004;110:1916-1919.
20. Montelascot G, Sideris G, Meuleman C, et al. A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes. J Am Coll Cardiol. 2006;48:931-938.
21. Price MJ, Coleman JL, Steinhubl SR, et al. Onset and offset of platelet inhibition after high-dose clopidogrel loading and standard daily therapy measured by a point-of-care assay in healthy volunteers. Am J Cardiol. 2006;98:681-684.
22. Von Beckerath N, Taubert D, Pogatsa-Murray G, et al. Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel. Circulation. 2005;112:2946-2950.
23. 12 receptor antagonist activity. Semin Thromb Hemost. 2005;31:184-194.
24. Sugidachi A, Asai F, Ogawa T, et al. The in vivo pharmacological profile of CS-747, a novel antiplatelet agent with platelet ADP receptor antagonist properties. Br J Pharmacol. 2000;129:1439-1446.
25. Kurihara A, Kazui M, Hagihara K, et al. Potent inhibition of platelet aggregation by prasugrel (CS-747, LY640315), a novel thienopyridine antiplatelet agent, is associated with covalent binding of active metabolite to ADP receptor [abstract], in European Society of Cardiology (ESC) Congress 2005; 2005 Sept 4-7; Stockholm, Sweden.
26. Farid N, McIntosh M, Garofolo F, et al. Determination of the active and inactive metabolites of prasugrel in human plasma by liquid chromatography/ tandem mass spectrometry. Rapid Commun Mass Spectrom. 2007;21:169-179.
27. Rehmel JL, Eckstein JA, Farid NA, et al. Interactions of two major metabolites of prasugrel, a thienopyridine antiplatelet agent, with the cytochromes P450. Drug Metab Dispos. 2006;34:600-607.
28. Paine MF, Hart HL, Ludington SS, et al. The human intestinal cytochrome p450 "pie." Drug Metab Dispos. 2006;34:880-886.
29. Farid NA, Smith RL, Gillespie TA, et al. The disposition of prasugrel, a novel thienopyridine, in humans. Drug Metab Dispos. 2007;35:1096-1104.
30. Small DS, Farid NA, Payne CD, et al. Prasugrel 60 mg and clopidogrel 300 mg loading doses: a pharmacokinetic basis for the observed difference in platelet aggregation response. Am J Cardiol. 2006;98(Suppl 8):200M.
31. Jakubowski JA, Sugidachi A, Ogawa T, et al. Comparative antiplatelet effects of the active metabolites of CS-747 (prasugrel, LY640315) and clopidogrel [Abstract]. J Thromb Haemost. 2005;3(Suppl 1):P2299.
32. Wiviott SD, Antman EM, Gibson M, et al. Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: Design and rationale for the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel thrombolysis in myocardial infarction 38 (TRITON-TIMI 38). Am Heart J. 2006;152:627-635.
33. Jakubowski JA, Stampfer MJ, Vaillancourt R, et al. Cumulative antiplatelet effect of low-dose enteric coated aspirin. Br J Haematol. 1985;60:635-642.
34. Takahashi M, Pang H, Kikuchi A, et al. Stabilization of the clopidogrel active metabolite in whole blood and its assay in human plasma by LC-MS/MS. J Am Soc Mass Spectrom. 2006;17:27S.
35. Lehmann, EL. Testing Statistical Hypotheses. 2nd edition, New York: John Wiley & Sons; 1986:18-22.
36. Weerakkody G, Brandt JT, Payne CD, et al. Clopidogrel poor responders: an objective definition based on Bayesian classification. Platelets. 2007;18:428-435.
37. Jernberg T, Payne CD, Winters KJ, et al. Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary heart disease. Eur Heart J. 2006;27:1166-1173.
38. Payne CD, Brandt JT, Weerakkody GJ, et al. Superior inhibition of platelet aggregation following a loading dose of CS-747 (Prasugrel, LY640315) versus clopidogrel: correlation with the pharmacokinetics of active metabolite generation [Abstract]. J Thromb Haemost. 2005;3(Suppl 1):P0952.
39. 12 receptor blockade but greater in vivo potency of CS-747 [Abstract]. J Thromb Haemost. 2005;3(Suppl 1):P1109.
40. Kazui M, Kurihara A, Hagihara K, et al. Prasugrel (CS-747, LY640315), a novel thienopyridine antiplatelet agent, more efficiently generates active metabolite compared to clopidogrel [Abstract]. Drug Metab Rev. 2005;37:98.
41. 14C-labeled clopidogrel. Semin Thromb Hemost. 1999;25:29-33.
42. Angiolillo D, Fernandez-Ortiz A, Bernardo E, et al. Variability in individual responsiveness to clopidogrel. J Am Coll Cardiol. 2007;49:1505-1516.
43. Brandt JT, Payne CD, Wiviott SD, et al. A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation. Am Heart J. 2007;153:66e9-66e16.
44. Hochholzer W, Trenk D, Bestehorn H-P, et al. Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement. J Am Coll Cardiol. 2006;48:1742-50.
45. Jakubowski JA, Payne CD, Weerakkody GJ, et al. Dose-dependent inhibition of human platelet aggregation by prasugrel and its interaction with aspirin in healthy subjects. J Cardiovasc Pharmacol. 2007;49:167-173.